in vitro News and Research

RSS

Univfy announces new IVF refund program

At the American Society for Reproductive Medicine Annual Meeting in Baltimore this year, Univfy, the global leader in predictive analytics for in vitro fertilization (IVF), announces a new program to help fertility providers qualify more patients for IVF refund programs.

19 Oct 2015

BET protein family plays key role in regulation of normal neuronal development and function

Regulation of a family of brain proteins known as bromodomain and extra-terminal domain containing transcription regulators (BETs) plays a key role in normal cognition and behavior, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published advanced online on September 21 and in print October 19 in The Journal of Experimental Medicine.

19 Oct 2015

Study shows why cancer anemia therapy stimulates tumor growth

Scientists have shown why a drug widely used to treat chemotherapy-induced anemia in ovarian and breast cancer patients also may shorten survival times in some patients by inadvertently stimulating tumor growth.

16 Oct 2015

US and German researchers team up to advance quality control of human stem cells

Researchers at The Scripps Research Institute (TSRI) in California, USA, and two German institutes, the Center for Integrated Psychiatry Kiel (ZIP) and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, have announced a partnership to advance the quality control of human stem cells.

16 Oct 2015

EKF’s PointMan™ used in cancer biopsy research

EKF, announces results from a study involving EKF Molecular’s PointMan™ DNA enrichment technology have been published in Clinical Cancer Research.

From EKF Diagnostics 15 Oct 2015

ARC Telehealth System allows fertility patients connect with medical professionals through mobile devices

ARC Fertility today announced its Telehealth System, designed to help fertility patients connect with medical professionals via mobile devices to improve communication, speed treatment and increase quality of care.

15 Oct 2015

Poorly-designed animal study threatens validity of preclinical research

Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to new a study from McGill University in Canada.

15 Oct 2015

FDA permits marketing of first CSF nucleic acid-based test for detection of multiple pathogens

The U.S. Food and Drug Administration today allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens that can cause central nervous system infections.

12 Oct 2015

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe.

From Oxford Gene Technology 6 Oct 2015

EKF Diagnostics to exhibit Maternal and Women's Health products at XXI FIGO World Congress

EKF, announces Maternal and Women's Health products at the International Federation of Gynecology and Obstetrics - in Vancouver, Canada, 4-9th October.

From EKF Diagnostics 6 Oct 2015

Genetic polymorphisms may serve as prognostic markers for lung cancer

Genetic polymorphisms associated with cancer progression lead to variations in gene expression and may serve as prognostic markers for lung cancer. Researchers at the Hiroshima University and Saitama Medical University found that in patients with lung cancer, a single nucleotide polymorphism (SNP) may regulate gene and protein expression and be associated with poor prognosis.

6 Oct 2015

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.

30 Sep 2015

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.

From EKF Diagnostics 29 Sep 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour tissue as a sample. The test identifies 42 mutations in the epidermal growth factor receptor (EGFR) gene, the most of any In-vitro Diagnostic (IVD) on the market, and can also be used as an aid in selecting eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).

From Roche Sequencing and Life Science 28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Standard clomiphene treatment better than proposed alternative for unexplained fertility

It is estimated that approximately 10 percent of women of child-bearing age may be unable to get pregnant or to carry a pregnancy to term.

26 Sep 2015

New study on deep-diving whales may help researchers create synthetic blood for human trauma patients

The ultra-stable properties of the proteins that allow deep-diving whales to remain active while holding their breath for up to two hours could help Rice University biochemist John Olson and his colleagues finish a 20-year quest to create lifesaving synthetic blood for human trauma patients.